Ondansetron Augmentation in Treatment-resistant OCD

Institute of Neuroscience, Florence, Italy21 enrolled

Overview

The aim of this study is to evaluate whether ondansetron augmentation to SSRI will improve and ondansetron discontinuation will result in worsening of obsessive compulsive symptoms among obsessive compulsive disorder resistant patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Obsessive Compulsive Disorder

Interventions

OndansetronDRUG

obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * a diagnosis of OCD established by clinical interview with a licensed psychiatrist; * a score of ≥ 24 at the Yale Brown Obsessive Compulsive Scale * a Clinical Global Inventory score ≥ 4, after over 12 weeks of treatment with an adequate trial of an selective serotonin reuptake inhibitor at a moderate to high dose Exclusion Criteria: * diagnoses of schizophrenia, schizoaffective disorder, organic mental disorder, bipolar disorder, current substance dependence or abuse, and current major depressive episode preceding the onset of obsessive compulsive disorder * undergoing concomitant behavior therapy * or having significant cardiovascular, hepatic, renal or pulmonary diseases

Locations (1)

Institute of Neuroscience

Florence, Florence, Italy